Shopping Cart
Remove All
Your shopping cart is currently empty
Emibetuzumab (Synonyms: LY2875358)
Catalog No. T76743 Copy Product Info
Purity: 95%
😃Good
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
Emibetuzumab
Copy Product Info😃Good
Catalog No. T76743
Synonyms LY2875358
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
Emibetuzumab
Cas No. 1365287-97-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $147 | In Stock | In Stock | |
| 5 mg | $447 | In Stock | In Stock | |
| 10 mg | $713 | In Stock | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.5% (SDS-PAGE); 98.8% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer. |
| In vitro | Emibetuzumab (LY2875358) inhibits HGF-stimulated proliferation of H596 at a concentration of 100 nmol/L for 6 days[1]. |
| In vivo | Emibetuzumab (LY2875358) exhibits antitumor effects on MET-amplified xenograft mouse tumor models. It inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice at a dose of 10 mg/kg via intravenous administration once a week for 5 weeks. Additionally, a single intravenous dose of 10 or 20 mg/kg results in the downregulation of MET and pMET levels in the tumors of mice. The antitumor effects persist when administered once a week for 3, 5, or 6 weeks at a dose of 10 mg/kg[1]. |
| Synonyms | LY2875358 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | HGFR/c-Met |
| Molecular Weight | 143.74 kDa |
| Cas No. | 1365287-97-3 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Emibetuzumab | purchase Emibetuzumab | Emibetuzumab cost | order Emibetuzumab | Emibetuzumab in vivo | Emibetuzumab in vitro | Emibetuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.